
    
      To be eligible for this study, patient tumor testing must demonstrate a genetic alteration
      resulting in the loss of function of the Histone Acetyltransferase (HAT) family genes, CREBBP
      and/or EP300, including gene deletions or selected inactivating mutations. If testing has not
      already been performed, the study will provide for the testing.
    
  